Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breakthrough trial tests Two-Pronged attack on deadly brain cancer

NCT ID NCT04446962

Ongoing Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding one of two targeted drugs (lenalidomide or ibrutinib) to standard chemotherapy works better for adults with newly diagnosed primary brain lymphoma. The trial first determines safe drug doses, then compares how well each combination shrinks tumors. Patients who respond well will receive a stem cell transplant to try to keep the cancer from returning.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CH Colmar

    Colmar, France

  • CH côte Basque

    Bayonne, 64100, France

  • CHRU Lille

    Lille, 69000, France

  • CHU Amiens

    Amiens, France

  • CHU Angers

    Angers, France

  • CHU Besançon

    Besançon, France

  • CHU Caen

    Caen, France

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU Créteil

    Créteil, France

  • CHU Dijon

    Dijon, France

  • CHU Grenoble

    Grenoble, France

  • CHU La Timone Marseille

    Marseille, France

  • CHU Limoges

    Limoges, France

  • CHU Lyon

    Lyon, France

  • CHU Nancy

    Nancy, France

  • CHU Nantes

    Nantes, France

  • CHU Nîmes - Carémeau

    Nîmes, 30029, France

  • CHU Pitié-Salpêtrière

    Paris, 75013, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rennes

    Rennes, 35000, France

  • CHU Strasbourg-Hôpital Hautepierre

    Strasbourg, 67098, France

  • CHU Tours

    Tours, France

  • Centre Henri Becquerel

    Rouen, 76000, France

  • Centre Lacassagne

    Nice, France

  • Hôpital Cochin

    Paris, 75006, France

  • IUCT -Oncopole

    Toulouse, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Curie

    Paris, 75005, France

Conditions

Explore the condition pages connected to this study.

CENTRAL NERVOUS SYSTEM NEOPLASMS, PRIMARY LYMPHOMA, LARGE B-CELL, DIFFUSE